The donation of scientific equipment marks the latest chapter in a long-standing alliance between the Catalan Cystic Fibrosis Association and the research teams at the Bellvitge Biomedical Research Institute (IDIBELL). This collaboration, spanning over ten years, has been instrumental in transforming the needs of individuals affected by cystic fibrosis into opportunities for scientific progress.
Cystic fibrosis is a genetic, chronic disease primarily affecting the respiratory and digestive systems. Despite being considered a rare disease, it is the most common inherited disorder among the Caucasian population, affecting one in every 5,000 people. Research has been crucial in improving diagnosis, monitoring, and treatment for patients.
The association's sustained support has helped consolidate research lines that have expanded knowledge of the genetic basis of cystic fibrosis and other hereditary pathologies, demonstrating the transformative role of initiatives born from patient associations.
This collaborative example gains particular relevance with the launch of the new transversal program for Adult Rare Disease Research, REMMA Bellvitge, by IDIBELL. The initiative aims to strengthen translational research in pathologies that, despite affecting thousands, still face significant diagnostic, therapeutic, and visibility challenges.
The relationship between the Catalan Cystic Fibrosis Association and IDIBELL serves as a prime example of success and the potential of long-term alliances between research and society, built around the shared goal of generating knowledge and improving the lives of those living with rare diseases.
IDIBELL, established in 2004, is a research center specializing in cancer, neuroscience, translational medicine, and regenerative medicine. It comprises over 1,500 professionals and 73 research groups, publishing more than 1,400 scientific articles annually.
